In Brief: HHS blood safety committee
This article was originally published in The Gray Sheet
Executive Summary
HHS blood safety committee: Department of Health and Human Services establishes an Advisory Committee on Blood Safety and Availability to advise the department on issues involving the nation's blood supply, according to an Oct. 23 Federal Register notice. Topics to be considered by the committee will include: "the implications of blood safety and availability of various economic factors affecting product cost and supply; definition of public health parameters around safety and availability of the blood supply; and broad public health, ethical and legal issues related to safety of the blood supply." HHS, which announced plans to form the committee in October 1995 ("The Gray Sheet" Oct. 16, 1995, I&W-9), calls for nominations of "authorities knowledgeable in blood banking, transfusion medicine, bioethics and related disciplines" to serve on the committee...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.